Theralase Research to be Presented at International Conference

Toronto, Ontario –October 30, 2017

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research will be presented at the 2018 International Society for Optical Engineering (“SPIE”) Photonics West to be held in San Francisco, California from January 27th to February 1st, 2018.

SPIE Photonics West is the world’s largest photonics technologies event, consisting of three conferences and two world-class exhibitions. Every year over 20,000 participants attend to learn more about the latest research and technology in: translational biophotonics, global healthcare, understanding the brain, new lasers for manufacturing, applications of 3D technologies, photonics-based consumer products and other related subject matters.

The “Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXVII” chairing committee have accepted “Targeting Non-Small Cell Lung Cancer by Novel TLD-1433-Mediated Photodynamic Therapy,” for oral presentation on January 27, 2018.

The “Therapeutics and Diagnostics in Urology” chairing committee has accepted, “Monitoring Irradiance During Full Bladder Irradiation for Ru(II) Photosensitizer Mediated Photodynamic Therapy in NMIBC,” for oral presentation on January 28, 2018.

Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase stated that, “The Company has previously reported that in the Phase Ib clinical study of Non-Muscle Invasive Bladder Cancer (“NMIBC”) that the first 3 patients treated at the Maximum Recommended Starting Dose (“MRSD”) were visibly free of tumours at 3 months post treatment. Theralase will now present to the scientific and medical community, the results that have shown the ability of TLD-1433-based PDT to destroy Non-Small Cell Lung Cancer (“NSCLC”) in various pre-clinical models. This latest peer-reviewed research supports the Company’s clinical mandate to advance the PDT technology platform across multiple oncological targets.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “This latest peer-reviewed research confirms that the Company is on the right track to provide support for the design and commencement of additional Phase Ib clinical studies, utilizing the Company’s cutting-edge PDT technology, for patients inflicted with various forms of this deadly disease.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Corporation”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

 

For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com